Revance Therapeutics soars following IPO

After pricing its 6M-share IPO at $16, Revance Therapeutics (RVNC) opened at $21 and is now at $26.25, up 64%.

The developer of novel botox products currently has a market cap of $465M.

Prospectus, IPO preview

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs